Orexigen Therapeutics, Inc. (OREX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.85+0.03 (+0.79%)
At close: 4:00 PM EDT
People also watch:
VVUSARNAKERXMNKDACHN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open3.80
Prev Close3.82
Bid3.51 x 700
Ask3.85 x 1500
Day's Range3.71 - 3.86
52wk Range3.18 - 34.40
1y Target EstN/A
Market Cap56.16M
P/E Ratio (ttm)-0.71
Beta1.82
Volume68,285
Avg Vol (3m)284,284
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cube13 days ago

    ETF’s with exposure to Orexigen Therapeutics, Inc. : August 15, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Orexigen Therapeutics, Inc. Here are 5 ETF’s with the largest exposure to OREX-US. Comparing the performance and risk of Orexigen Therapeutics, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
    Capital Cube16 days ago

    Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Orexigen Therapeutics, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Orexigen Therapeutics, Inc. – Arena Pharmaceuticals, Inc., VIVUS, Inc., Zafgen, Inc., Boston Scientific Corporation, Johnson & Johnson, Bristol-Myers Squibb Company and Athersys, Inc. (ARNA-US, VVUS-US, ZFGN-US, ... Read more (Read more...)

  • Associated Press24 days ago

    Orexigen reports 2Q loss

    On a per-share basis, the La Jolla, California-based company said it had a loss of $1.73. The drug developer for obesity and weight loss posted revenue of $7.8 million in the period. In the final minutes ...